Management attributes the termination of the Alcon merger to the Federal Trade Commission’s intent to enjoin the deal, leading to a mutual pragmatic decision to remain independent.
The acquisition process caused a 13-month period of operational disruption, particularly impacting international distributor activity and domestic customer decision-making due to future uncertainty.
Despite transaction headwinds, the ALLY system achieved a 50% increase in installed base and 22% procedure growth in 2025, which management views as validation of the product’s technological superiority.
Market share gains are driven by replacing first-generation competitive lasers and expanding into ‘femto-naive’ surgeon segments, which accounted for 50% of Q4 2025 systems.
The company is leveraging its ‘nimble’ organizational structure to re-engage with stakeholders, aided by vendor concessions and the retention of a $10 million transaction deposit.
Operational outperformance is linked to the ALLY system’s efficiency, with U.S. units performing 27% more procedures annually than the national average for laser-assisted cataract surgery.
Management anticipates a gradual return to historical operating performance over several quarters as international distributors re-engage with tenders and marketing activities.
Fiscal 2026 gross margin is projected to improve to the 46% to 49% range, though the final figure will depend on the mix of system sales versus higher-margin recurring revenue.
Cash-based operating expenses are expected to increase by no more than 10% in 2026, with the majority of new spending allocated to commercial activities to regain lost momentum.
The company plans to explore new geographic markets, including Australia, New Zealand, and parts of Latin America, to capitalize on the replacement cycle of aging competitive systems.
Strategic focus remains on growing recurring revenue through increased utilization of the existing 200-unit ALLY installed base and new placements in office-based surgery suites.
LENSAR retained a $10 million merger deposit, which will be reclassified from a liability to equity in the first quarter of 2026.
Acquisition-related liabilities were reduced by a $4.3 million advisor concession, with the remaining $5 million deferred until May 2027 to preserve near-term liquidity.
2025 margins were pressured by inflationary raw material costs and tariffs that the company chose not to pass on to customers to maintain competitive positioning.
International recovery remains a risk factor as management notes that distributors’ immediate forecasts remain conservative following the year-long pause in activity.
